April 18th 2024
Pembrolizumab also demonstrated a disease-free survival benefit vs placebo for patients with clear-cell renal cell carcinoma.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Lenvatinib/Everolimus Combo May Be Acceptable After Immunotherapy in Clear Cell RCC
February 11th 2021Based on an exploratory analysis of a phase 2 trial, lenvatinib plus everolimus appears to be an acceptable treatment option for patients receiving prior immunotherapy for clear cell renal cell carcinoma.
Assays of Intratumoral Heterogeneity May Predict RCCs Likely to Respond to PD-1 Blockade
January 21st 2021“Our results suggest that low [intertumoral heterogeneity] is associated with increased response to anti–PD-1 immunotherapy in renal cell carcinoma through increased immune activity involving more neoantigens and less frequent immune evasion,” wrote the study authors, led by Xia Ran.
Phase 2 CANTATA Study of Telaglenastat Fails to Meet Primary End Point for Advanced Clear Cell RCC
January 4th 2021Combination treatment with telaglenastat (CB-839) and cabozantinib (Cabometyx) did not meet the study’s primary end point of improved progression-free survival versus cabozantinib alone in patients with advanced or metastatic clear cell renal cell carcinoma.
Ramaprasad Srinivasan, MD, PhD, on the Results of MK-6482 in VHL Associated Disease
December 23rd 2020Study results indicated that MK-6482 demonstrated durable efficacy in patients with Von Hippel-Lindau disease-associated clear cell renal cell carcinoma, pancreatic lesions, and hemangioblastomas by targeting the underlying pathophysiology of the disease.
Ramaprasad Srinivasan, MD, PhD, on the Design of the Study of MK-6482 in VHL-Associated Disease
December 14th 2020Data presented at SUO indicated that MK-6482 demonstrated durable efficacy in patients with Von Hippel-Lindau disease-associated clear cell renal cell carcinoma, pancreatic lesions, and hemangioblastomas by targeting the underlying pathophysiology of the disease.
Robert A. Figlin, MD, Discusses 2020 Treatment Advances for Patients with RCC
December 10th 2020The expert from Cedars-Sinai Cancer spoke about the continued integration of immunotherapy-based combination regimens, and the importance of utilizing the multidisciplinary care team to mitigate any possible toxicities that may arise.
Active Surveillance a Safe Strategy for Patients with Small Renal Masses Suspicious for RCC
December 4th 2020A study from the 21st Annual Meeting of the Society of Urologic Oncology concluded that active surveillance is a safe management strategy for patients with small renal masses suspicious for renal cell carcinoma.
HIF-2α Inhibition Warranted for VHL-Associated Clear Cell Renal Cell Carcinoma
December 4th 2020The novel first-in-class small molecule inhibitor of HIF-2α, PT2385 demonstrated the ability to stabilize disease with tolerable safety in patients with von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC) and non-renal tumors, according to results presented in a poster during the 21st Annual Meeting of the Society of Urologic Oncology (SUO).
Cytoreductive Nephrectomy, Immunotherapy-Based Systemic Therapy Induce Benefit in mRCC
December 3rd 2020A pooled analysis compared survival among patients with metastatic renal cell carcinoma treated with cytoreductive nephrectomy and either targeted therapy or immunotherapy regimens utilizing checkpoint inhibitors.
Lenvatinib in Combination with Pembrolizumab or Everolimus Shows Promise for Advanced RCC
November 10th 2020The phase 3 KEYNOTE-581/CLEAR trial (Study 307) demonstrated that both combinations saw meaningful improvements in the study’s primary end point of progression-free survival for patients with advanced renal cell carcinoma.
Lower Starting Dose of Lenvatinib in RCC Does not Meet Non-Inferiority Threshold
November 9th 2020The results of the phase 2 Study 218 indicated that the lower starting dose of 14 mg of lenvatinib (Lenvima) did not meet the threshold for non-inferiority compared to the FDA-approved starting dose of 18 mg.
Cabozantinib Appears to be More Effective for Treating Advanced RCC Compared with Sunitinib
November 1st 2020First-line cabozantinib was found to provide longer quality-adjusted time without symptoms of disease or toxicity of treatment (Q-TWiST) in patients with advanced renal cell carcinoma when compared with sunitinib.
BIONIKK Trial Sees Improved Responses with Molecularly-Guided Therapy in Patients with mRCC
September 23rd 2020Findings from the noncomparative, phase 2, biomarker-driven BIONIKK trial support the use of molecularly-directed frontline therapy as means to enrich responses in patients with metastatic clear cell renal cell carcinoma.
Study Supports Nivolumab/Cabozantinib as Frontline Option in Advanced Renal Cell Carcinoma
September 19th 2020“With expanding options for patients with advanced RCC, the overall efficacy, safety, and quality of life benefits, as well as individual patient characteristics, are very important considerations when you select appropriate therapy.”
4-Year Results from Phase 3 CheckMate-214 Trial Continue to Show Long-Term Benefit in RCC
September 18th 2020With a follow-up of 4 years, nivolumab plus ipilimumab continued to demonstrate superior, long-term overall survival and durable responses compared to sunitinib in patients with advanced renal cell carcinoma.
Exelexis Files sNDA to FDA for Cabozantinib, Nivolumab Combo in Advanced RCC
August 25th 2020The application was based on results observed in the pivotal, phase 3 CheckMate-9ER trial evaluating cabozantinib in combination with nivolumab compared with sunitinib in previously untreated patients with advanced or metastatic RCC.
FDA Grants Breakthrough Therapy Designation, Orphan Drug Designation to MK-6482
July 29th 2020The FDA granted breakthrough therapy designation to MK-6482 for the treatment of patients with von Hippel-Lindau disease-associated renal cell carcinoma and orphan drug designation to MK-6482 for von Hippel-Lindau disease.
Elizabeth Plimack, MD, MS, on Depth of Response in from the KEYNOTE-426 Trial
June 28th 2020Elizabeth Plimack, MD, MS, discussed the depth of response for patients included in the KEYNOTE-426 trial investigating axitinib and pembrolizumab over sunitinib for patients with advanced renal cell carcinoma.